Earnings ·
Beam Therapeutics reports Q3 net loss of $1.28 per share and $1.0B cash position
BEAMBeam Therapeutics Inc.
Beam Therapeutics reported a third-quarter 2026 net loss of $134.4 million, or $1.28 per share, compared to a loss of $112.6 million in the prior-year period. Research and development expenses rose to $110.1 million from $109.8 million, while general and administrative costs increased to $31.5 million from $26.7 million. The company ended the quarter with $1.0 billion in cash, cash equivalents, and marketable securities. Management expects this balance, combined with a potential $200 million draw from a Sixth Street facility, to fund operations into mid-2029. Clinically, Beam highlighted durable data for BEAM-302 in alpha-1 antitrypsin deficiency, initial proof-of-concept for BEAM-301 in glycogen storage disease type Ia, and plans to initiate dosing for BEAM-304 in phenylketonuria early next year. The company also anticipates submitting a U.S. Biologics License Application for risto-cel in sickle cell disease as early as year-end 2026. Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing.